FDA panel members have mixed views on biotech salmon

09/20/2010 | New York Times (tiered subscription model), The

A panel advising the Food and Drug Administration said AquaBounty Technologies' biotech salmon would be safe for human consumption and seem to pose no safety risk to the environment. However, some members of the committee said they found some flaws in the studies that back the safety of the biotech fish, including the small number of fish tested. The FDA was set to hold a public hearing today to discuss whether biotech salmon should carry a label signifying genetic modification.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC